Astal Laboratories Q1 Cons. Revenue at ₹100.94 Cr; Standalone PAT Rises 77% YoY to ₹3.71 Cr
Astal Laboratories reported consolidated revenue from operations of ₹100.94 Cr (₹10,093.58 Lakhs) for the quarter ended June 30, 2026. On a standalone basis, revenue grew 56.0% YoY to ₹39.51 Cr from ₹25.33 Cr, with standalone net profit increasing 77.4% YoY to ₹3.71 Cr compared to ₹2.09 Cr in the previous year quarter. The company's wholly owned subsidiary, Sriven Pharmachem India Private Limited, contributed ₹61.53 Cr in revenue and ₹5.71 Cr in net profit during the quarter. The business operates in a single segment focused on the manufacturing and trading of Active Pharmaceutical Ingredients (Bulk Drugs).
உச்சம் நம்பிக்கை
என்ன மாறியதுAstal Laboratories released its Q1 financial results, showing significant scale expansion from the consolidation of its subsidiary Sriven Pharmachem India.
ஏன் இது முக்கியம்The inclusion of Sriven Pharmachem expands total quarterly revenue baseline to over ₹100 Cr, substantially boosting operational scale in the bulk drugs segment.
Consolidated Revenue: ₹10,093.58 லட்சம்Standalone Revenue: ₹3,951.47 லட்சம்Standalone PAT: ₹370.69 லட்சம்Subsidiary Revenue Contribution: ₹6,152.77 லட்சம்Subsidiary PAT Contribution: ₹571.48 லட்சம்
📅 குறுகிய காலம்Earnings show healthy standalone YoY growth and scale expansion from subsidiary integration, which may support near-term sentiment.
📈 நீண்ட காலம்Sustainable long-term performance hinges on profitability in the API business and stability in corporate governance given the low promoter stake.
⚠ அபாய எச்சரிக்கைகள்
- Significantly low promoter holding (4.53% as of June 2026, down from 18.19% in Dec 2025)
- High concentration of consolidated revenue in the subsidiary Sriven Pharmachem (>60% of total)
👀 கவனிக்க வேண்டியவை
Monitor whether the consolidated revenue run-rate above ₹100 Cr and subsidiary margins sustain in upcoming quarters, alongside tracking the low promoter shareholding.
